UPC Analytics
DEEN
Übersicht · Eingereicht: 13. Sept. 2024

UPC_CoA_528/2024

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

BerufungenHauptberufungCourt of AppealAppealCase Closed
ÜbersichtEntscheidungenZitateDokumenteZeitverlauf
Parteien

Kläger

Vertreter: Daniel Wise (Carpmaels & Ransford); Niels Hölder (Carpmaels & Ransford)

Beklagte

Vertreter: Koen Bijvank (Brinkhof N.V.); (Bardehle Pagenberg)
Richter
  • Klaus Grabinski
  • Nathalie Sabotier
  • Peter Blok
Patente
  • EP3666797
  • EP 3 666 797
CPC-Codes: C07K2317/14, C07K2317/34, A61K39/395, A61K2039/505, A61K31/366, A61P3/06, A61K31/66, A61K31/22, A61P9/00, A61P7/00, A61P25/28, A61K2300/00…

Sektor: Biotechnology

Ausgang
Abgewiesen
Eingereicht: 13. Sept. 2024
Erste Entscheidung: 25. Nov. 2025
Letzte Entscheidung: 25. März 2026
Sprache: English

The Court of Appeal (Panel with Klaus Grabinski, Nathalie Sabotier, Peter Blok) rejected Sanofi and Regeneron's application for suspensive effect concerning the Court of Appeal's own decision of 25 November 2025 which had rejected the requests for revocation of EP 3 666 797. Sanofi and Regeneron sought suspensive effect as part of a petition for rehearing (R. 220.4 RoP). The court found no basis to suspend a revocation-rejection decision (as this had no practical effect on the patent's validity status), and rejected the claim that the CoA's reasoning on claim interpretation and inventive step was based on issues not argued by the parties.

Im UPC-Register öffnen